This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2006 Jul 1;12(13):4127; author reply 4127-9.

doi: 10.1158/1078-0432.CCR-06-0461.

ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer

Sharon Marsh, Cristi R King, Howard L McLeod, Jim Paul, Gillian Gifford, Robert Brown

PMID: 16818714
DOI: 10.1158/1078-0432.CCR-06-0461

Comment

ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer

Sharon Marsh et al. Clin Cancer Res. 2006.

. 2006 Jul 1;12(13):4127; author reply 4127-9.

doi: 10.1158/1078-0432.CCR-06-0461.

Authors

Sharon Marsh, Cristi R King, Howard L McLeod, Jim Paul, Gillian Gifford, Robert Brown

PMID: 16818714
DOI: 10.1158/1078-0432.CCR-06-0461

No abstract available

PubMed Disclaimer

Comment on

mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
Gréen H, Söderkvist P, Rosenberg P, Horvath G, Peterson C. Gréen H, et al. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):854-9. doi: 10.1158/1078-0432.CCR-05-0950. Clin Cancer Res. 2006. PMID: 16467099 Clinical Trial.

Similar articles

ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H; AOCS Study Group; Harnett PR, Brown R, DeFazio A, Chenevix-Trench G. Johnatty SE, et al. Clin Cancer Res. 2008 Sep 1;14(17):5594-601. doi: 10.1158/1078-0432.CCR-08-0606. Clin Cancer Res. 2008. PMID: 18765553
ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.
Gréen H, Söderkvist P, Rosenberg P, Horvath G, Peterson C. Gréen H, et al. J Pharm Sci. 2008 Jun;97(6):2045-8. doi: 10.1002/jps.21169. J Pharm Sci. 2008. PMID: 17828752
Optimizing primary chemotherapy in ovarian cancer.
Markman M. Markman M. Hematol Oncol Clin North Am. 2003 Aug;17(4):957-68, viii. doi: 10.1016/s0889-8588(03)00058-3. Hematol Oncol Clin North Am. 2003. PMID: 12959185 Review.
ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.
Björn N, Jakobsen Falk I, Vergote I, Gréen H. Björn N, et al. Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):277-287. doi: 10.1111/bcpt.12997. Epub 2018 Apr 19. Basic Clin Pharmacol Toxicol. 2018. PMID: 29504705 Clinical Trial.
[Combination chemotherapy with docetaxel and carboplatin for epithelial ovarian cancer].
Misawa H, Ochiai K, Yasuda M, Tanaka T. Misawa H, et al. Nihon Rinsho. 2004 Oct;62 Suppl 10:546-9. Nihon Rinsho. 2004. PMID: 15535305 Review. Japanese. No abstract available.

See all similar articles

Cited by

No Association between ABCB1 G2677T/A or C3435T Polymorphisms and Survival of Breast Cancer Patients-A 10-Year Follow-Up Study in the Polish Population.
Totoń E, Jacczak B, Barczak W, Jagielski P, Gryczka R, Hołysz H, Grodecka-Gazdecka S, Rubiś B. Totoń E, et al. Genes (Basel). 2022 Apr 21;13(5):729. doi: 10.3390/genes13050729. Genes (Basel). 2022. PMID: 35627114 Free PMC article.
Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.
He YJ, Winham SJ, Hoskins JM, Glass S, Paul J, Brown R, Motsinger-Reif A, McLeod HL. He YJ, et al. Pharmacogenomics J. 2016 Jun;16(3):243-8. doi: 10.1038/tpj.2015.52. Epub 2015 Jul 21. Pharmacogenomics J. 2016. PMID: 26194361 Clinical Trial.
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD. Sissung TM, et al. Clin Cancer Res. 2008 Jul 15;14(14):4543-9. doi: 10.1158/1078-0432.CCR-07-4230. Clin Cancer Res. 2008. PMID: 18628469 Free PMC article.
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Lee CK, et al. Br J Cancer. 2011 Jul 26;105(3):360-5. doi: 10.1038/bjc.2011.256. Epub 2011 Jul 12. Br J Cancer. 2011. PMID: 21750553 Free PMC article. Clinical Trial.
Germline genetic variants with implications for disease risk and therapeutic outcomes.
Pasternak AL, Ward KM, Luzum JA, Ellingrod VL, Hertz DL. Pasternak AL, et al. Physiol Genomics. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017. Epub 2017 Sep 8. Physiol Genomics. 2017. PMID: 28887371 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information